Canada markets closed

Precipio, Inc. (PRPO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
6.03+0.07 (+1.09%)
At close: 04:00PM EDT
5.83 -0.20 (-3.40%)
After hours: 06:44PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Precipio Secures a short-term $500K Credit Facility

    Loan will supplement any temporary cashflow deficit related to cash collections delay due to Change Healthcare cybersecurity attackNEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare, a healthcare billing company used by a significant part of the healthcare market. Ma

  • GlobeNewswire

    Precipio Announces Year end 2023 Shareholder Update Call

    Conference Call to be held on April 1st, 2024 at 5:00 PM EDTNEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc.

  • GlobeNewswire

    Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY

    Company continues to make strides towards breakevenNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year. Both pathology and products divisions have demonstrated substantial growth from 2023, with the pathology services division increasing revenue by 52%, and the products division incr